Capricor TherapeuticsCAPR
About: Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Employees: 160
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 17
133% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 15
88% more capital invested
Capital invested by funds: $127M [Q3] → $239M (+$112M) [Q4]
44% more funds holding
Funds holding: 75 [Q3] → 108 (+33) [Q4]
25% more call options, than puts
Call options by funds: $33.1M | Put options by funds: $26.6M
12.38% more ownership
Funds ownership: 25.72% [Q3] → 38.1% (+12.38%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Cantor Fitzgerald Kristen Kluska 23% 1-year accuracy 23 / 100 met price target | 128%upside $30 | Overweight Reiterated | 20 Mar 2025 |
HC Wainwright & Co. Joseph Pantginis 15% 1-year accuracy 61 / 413 met price target | 486%upside $77 | Buy Reiterated | 20 Mar 2025 |
Financial journalist opinion
